Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRK124 (Pyratine-XR) is a topical dermatological agent formulated as a 0.125% moisturizing lotion for the treatment of mild-to-moderate rosacea. Its active ingredient, furfuryl tetrahydropyranyladenine, is a synthetic analog of the plant cytokinin kinetin. Developed by Senetek PLC, PRK124 is designed to improve skin barrier function and reduce the clinical signs of rosacea, including erythema (redness) and inflammatory papules. The compound is noted for its high tolerability and lack of skin irritation, which is particularly beneficial for rosacea patients who typically exhibit hypersensitive skin. Clinical data supports its efficacy and safety for long-term use up to 48 weeks.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pyratine-XR.